Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

The efficacy of CAR-T cell therapy against poorly responding tumors has been enhanced by administering the cells in combination with immune checkpoint blockade inhibitors. Alternatively, the CAR construct has been engineered to co-express factors that boost CAR-T cell function in the tumor microenvi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rafiq, Sarwish, Yeku, Oladapo O., Jackson, Hollie J., Purdon, Terence J., van Leeuwen, Dayenne G., Drakes, Dylan J., Song, Mei, Miele, Matthew M., Li, Zhuoning, Wang, Pei, Yan, Su, Xiang, Jingyi, Ma, Xiaojing, Seshan, Venkatraman E., Henderickson, Ronald C., Liu, Cheng, Brentjens, Renier J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126939/
https://www.ncbi.nlm.nih.gov/pubmed/30102295
http://dx.doi.org/10.1038/nbt.4195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126939/
https://www.ncbi.nlm.nih.gov/pubmed/30102295
http://dx.doi.org/10.1038/nbt.4195

Ejemplares similares